A Promising Drug Target: IGLV4-60, a Polymorphic light chain immunoglobulin, its research significance as a target

Target Name: IGLV4-60

NCBI ID: G28785

IGLV4-60

Other Name(s): Immunoglobulin lambda variable 4-60 | V5-4 | IGLV460 | immunoglobulin lambda variable 4-60

A Promising Drug Target: IGLV4-60, a Polymorphic light chain immunoglobulin, its research significance as a target

Summary

Immunoglobulin lambda variable 4-60 (IGLV4-60) is a single-chain, variable region immunoglobulin with multiple biological functions. In recent years, scientists have discovered that IGLV4-60 plays an important role in a variety of tumors, autoimmune diseases, and immunodeficiency diseases. This article aims to explore the research significance of IGLV4-60 as a drug target and provide new ideas for research in related fields.

introduction

Immunoglobulin light chain (IGL) is an important component of the immune system. Its main function is to bind pathogens and participate in immune response and immune regulation. IGLs play key roles in a variety of biological processes. In recent years, with the rapid development of science and technology, people's research on IGL has also achieved fruitful results. However, IGL remains an extremely challenging target in drug research.

IGLV4-60 is a member of the IGL family, and its light chain consists of 4 to 60 amino acids. IGLV4-60 plays an important role in a variety of physiological and pathological processes, such as promoting B cell proliferation and activation, and participating in cellular immune responses. At the same time, IGLV4-60 has potential application value in tumors, autoimmune diseases, and immunodeficiency diseases.

As a drug target, IGLV4-60 has the following advantages:

1. High specificity: IGLV4-60, as an immunoglobulin light chain, is highly specific. Its light chain structure is unique and different from other immunoglobulins, which makes IGLV4-60 have higher stability and affinity, which is conducive to the specific binding of drugs to it.

2. Various biological functions: IGLV4-60 plays an important role in a variety of biological processes and has high application value as a drug target. For example, studies have shown that IGLV4-60 is involved in cell proliferation, differentiation, apoptosis and other processes, and is closely related to tumor occurrence and development. In addition, IGLV4-60 plays a role in immune response, participates in cellular immune response, and plays an important regulatory role in the immune system.

3. As a new biomarker: In recent years, people have gradually paid more and more attention to the expression level of IGLV4-60 in tumors and other diseases. Studies have shown that the expression level of IGLV4-60 is negatively correlated with the survival rate of tumor patients, and its expression level can be used as an important indicator of the prognosis of tumor patients. In addition, the expression level of IGLV4-60 can also be used for diagnosis and treatment monitoring of autoimmune diseases and immunodeficiency diseases.

4. Drug research and development: In recent years, drug research and development targeting IGLV4-60 has made certain progress. For example, monoclonal antibodies and targeted drugs targeting IGLV4-60 have entered the clinical trial stage, laying the foundation for drug target research on IGLV4-60.

The research significance of IGLV4-60 as a drug target

1. Drug research and development: IGLV4-60 has high research value as a drug target. By studying the biological functions, structural characteristics and relationship between IGLV4-60 and tumors and other diseases, we can explore its application potential in the pharmaceutical field and provide new treatment options for patients.

2. Personalized treatment: The expression level of IGLV4-60 can be used as an important basis for personalized treatment of tumor patients. By analyzing the expression levels of IGLV4-60, appropriate treatment options can be selected for patients and the treatment effect can be improved.

3. Disease diagnosis and treatment monitoring: IGLV4-60 has potential application value in tumors, autoimmune diseases and immunodeficiency diseases. By studying the expression levels and biological functions of IGLV4-60, we can provide important theoretical and experimental basis for the diagnosis and treatment of these diseases.

4. Biomarker: The expression level of IGLV4-60 in tumors and other diseases can be used as a biomarker for disease diagnosis, prognosis and treatment monitoring.

Protein Name: Immunoglobulin Lambda Variable 4-60

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV4-60 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV4-60 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets